Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Inclusion Criteria: * Diagnosis with SARS-CoV-2 by the currently available assays (Food and Drug Administration \[FDA\] approved) * Should be hospitalized and exhibit at least one of the following predictors of mortality * Age \>= 65 years * Current smoker (smoked \>= 100 cigarettes in life and actively smoking) * Chronic obstructive pulmonary disease (COPD) * Diabetes * Hypertension * Coronary artery disease * Cerebrovascular accident (CVA) * Chronic renal disease (creatinine of \>= 2 mg/dl) * Cancer * Patients that have C-reactive protein (CRP) \>= 10 mg/L * D-dimer \>= 0.5 mg/L * Procalcitonin \>= 0.5 mg/L * Lactate dehydrogenase (LDH) \>= upper limit of normal (ULN) * Patients or authorized family member willing to sign informed consent to participate in this study Exclusion Criteria: * Pregnant or lactating women * Hypersensitivity to tocilizumab * Patients or authorized family member unwilling to sign informed consent to participate in this study * Uncontrolled tuberculosis, or any uncontrolled fungal infection (eg: candidemia)